AMR Stakeholder Profile
Novo Holdings REPAIR Impact Fund
Focus area/active in: Therapeutics
Company/Organisation type: Accelerator | Finance | Investor
Novo Holdings established the REPAIR Impact Fund commissioned by the Novo Nordisk Foundation in February 2018 with a total budget of USD 165 million to invest in companies involved in discovering and the early-stage development of therapies targeting resistant microorganisms. The fund is expected to invest USD 20 million to 40 million per year over 3–5 years in about 20 projects, which is anticipated to yield at least one new therapy reaching the market. The REPAIR Impact Fund will invest in start-ups, early-stage companies and corporate spin-outs. Our philosophy is to support ambitious programmes addressing antimicrobial resistance through a broad range of therapeutic modalities. REPAIR is an acronym: Replenishing and Enabling the Pipeline for Anti-Infective Resistance.
Would you like to meet Repair Impact Fund virtually during the AMR Conference week?
Get in touch!
Please fill out the form below to get in touch with us.